Sodium phosphate, dibasic

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Sodium phosphate, dibasic
Accession Number
DB14502  (DBSALT001976)
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • Dibasic sodium phosphate anhydrous
  • Dibasic sodium phosphate, anhydrous
  • Disodium acid phosphate
  • Disodium hydrogen monophosphate
  • Disodium hydrogen phosphate
  • Disodium hydrogen phosphate, anhydrous
  • disodium hydrogenphosphate
  • Disodium phosphate
  • Phosphoric acid, disodium salt, anhydrous
  • Phosphoric acid, sodium salt (1:2)
  • Sodium phosphate dibasic
  • Sodium phosphate, dibasic
  • Sodium phosphate, dibasic (anhydrous)
  • Sodium phosphate, dibasic anhydrous
  • Sodium phosphate, dibasic, anhydrous
  • Sodium phosphate,dibasic,anhydrous
External IDs
E-339(II) / Fema no. 2398 / INS NO.339(II) / INS-339(II)
Product Ingredients
IngredientUNIICASInChI Key
Sodium phosphate, dibasic dihydrate94255I6E2T10028-24-7KDQPSPMLNJTZAL-UHFFFAOYSA-L
Sodium phosphate, dibasic dodecahydrateE1W4N241FO10039-32-4DGLRDKLJZLEJCY-UHFFFAOYSA-L
Sodium phosphate, dibasic, heptahydrate70WT22SF4B7782-85-6PYLIXCKOHOHGKQ-UHFFFAOYSA-L
Sodium phosphate, dibasic, monohydrateBWZ7K44R51118830-14-1LVXHNCUCBXIIPE-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Phosphate ionionicNK08V8K8HR14265-44-2NBIIXXVUZAFLBC-UHFFFAOYSA-K
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aminosyn II 7% M In 10% Dextrose(dual Chamber)Sodium phosphate, dibasic (49 mg) + Alanine (348 mg) + Arginine (356 mg) + Aspartic acid (245 mg) + Dextrose, unspecified form (5 g) + Glutamic acid (258 mg) + Glycine (175 mg) + Histidine (105 mg) + Isoleucine (231 mg) + L-Lysine (368 mg) + Leucine (350 mg) + Magnesium chloride (30 mg) + Methionine (60 mg) + N-acetyltyrosine (94 mg) + Phenylalanine (104 mg) + Potassium chloride (97 mg) + Proline (252 mg) + Serine (186 mg) + Sodium chloride (120 mg) + Threonine (140 mg) + Tryptophan (70 mg) + Valine (175 mg)SolutionIntravenousHospira Healthcare Ulc1987-12-312012-08-03Canada
Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)Sodium phosphate, dibasic (49 mg) + Alanine (422 mg) + Arginine (432 mg) + Aspartic acid (298 mg) + Dextrose, unspecified form (10 g) + Glutamic acid (314 mg) + Glycine (212 mg) + Histidine (128 mg) + Isoleucine (280 mg) + L-Lysine (446 mg) + Leucine (425 mg) + Magnesium chloride (30 mg) + Methionine (73 mg) + N-acetyltyrosine (115 mg) + Phenylalanine (126 mg) + Potassium chloride (97 mg) + Proline (307 mg) + Serine (225 mg) + Sodium chloride (120 mg) + Threonine (170 mg) + Tryptophan (85 mg) + Valine (212 mg)SolutionIntravenousHospira Healthcare Ulc1987-12-312012-08-03Canada
Aminosyn II and DextroseSodium phosphate, dibasic (49.3 mg/100mL) + Alanine (422 mg/100mL) + Arginine (432 mg/100mL) + Aspartic acid (298 mg/100mL) + D-glucose monohydrate (10 g/100mL) + Glutamic acid (314 mg/100mL) + Glycine (212 mg/100mL) + Histidine (128 mg/100mL) + Isoleucine (280 mg/100mL) + L-Lysine acetate (446 mg/100mL) + Leucine (425 mg/100mL) + Magnesium chloride hexahydrate (30 mg/100mL) + Methionine (73 mg/100mL) + N-acetyltyrosine (115 mg/100mL) + Phenylalanine (126 mg/100mL) + Potassium chloride (97 mg/100mL) + Proline (307 mg/100mL) + Serine (225 mg/100mL) + Sodium chloride (120 mg/100mL) + Threonine (170 mg/100mL) + Tryptophan (85 mg/100mL) + Valine (212 mg/100mL)Injection, solutionIntravenousHospira, Inc.1988-11-012010-01-01Us
Amo Endosol ExtraSodium phosphate, dibasic (0.42 mg) + Calcium Chloride (0.154 mg) + Dextrose, unspecified form (0.92 mg) + Glutathione disulfide (0.184 mg) + Magnesium chloride (0.2 mg) + Potassium chloride (0.38 mg) + Sodium bicarbonate (2.1 mg) + Sodium chloride (7.14 mg)Powder, for solutionIntraocularAmo Canada Company1993-12-312008-07-30Canada
Bss PlusSodium phosphate, dibasic (0.042 %) + Calcium Chloride (0.0154 %) + Dextrose, unspecified form (0.092 %) + Glutathione disulfide (0.0184 %) + Magnesium chloride (0.02 %) + Potassium chloride (0.038 %) + Sodium bicarbonate (0.21 %) + Sodium chloride (0.714 %)Kit; SolutionIntraocularAlcon, Inc.1982-12-31Not applicableCanada
Eyesaline EyewashSodium phosphate, dibasic (0.84 %) + Sodium chloride (0.44 %) + Sodium phosphate, monobasic (0.14 %)LiquidIrrigationFendall, Inc.1998-04-162005-08-25Canada
FleetSodium phosphate, dibasic, heptahydrate (7 g/133mL) + Sodium phosphate, monobasic, unspecified form (19 g/133mL)EnemaRectalC.B. Fleet Company, Inc.1954-01-01Not applicableUs
FleetSodium phosphate, dibasic, heptahydrate (2.7 g/45mL) + Sodium phosphate, monobasic, unspecified form (7.2 g/45mL)LiquidOralC.B. Fleet Company, Inc.2011-11-07Not applicableUs
FleetSodium phosphate, dibasic, heptahydrate (2.7 g/45mL) + Sodium phosphate, monobasic, unspecified form (7.2 g/45mL)LiquidOralC.B. Fleet Company, Inc.2005-05-14Not applicableUs
FleetSodium phosphate, dibasic, heptahydrate (7 g/133mL) + Sodium phosphate, monobasic, unspecified form (19 g/133mL)EnemaRectalC.B. Fleet Company, Inc.2011-03-15Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralKaiser Foundations Hospitals2014-07-07Not applicableUs
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralRising Pharmaceuticals, Inc.2012-06-28Not applicableUs
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralCardinal Health2012-06-282018-05-17Us55154 767620180907 15195 nnrmgf
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralAvera McKennan Hospital2015-03-112018-06-05Us69189 010420180907 15195 1028m42
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralCarilion Materials Management2012-06-28Not applicableUs64980 0104 01 nlmimage10 cc046643
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralAmerican Health Packaging2014-05-132020-06-30Us
K Phos NeutralSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)Tablet, coatedOralBeach Products, Inc.1977-04-11Not applicableUs0486 112520180907 15195 1fdxkci
Sodium PhosphatesSodium phosphate, dibasic (142 mg/1mL) + Sodium phosphate, monobasic, monohydrate (276 mg/1mL)Injection, solutionIntravenousFresenius Kabi2000-09-06Not applicableUs
Sodium PhosphatesSodium phosphate, dibasic (142 mg/1mL) + Sodium phosphate, monobasic, monohydrate (276 mg/1mL)Injection, solutionIntravenousCardinal Health1990-09-302018-06-25Us
Sodium PhosphatesSodium phosphate, dibasic (142 mg/1mL) + Sodium phosphate, monobasic, monohydrate (276 mg/1mL)Injection, solutionIntravenousAmerican Regent1990-09-302013-10-01Us
Categories
UNII
22ADO53M6F
CAS number
7558-79-4
Weight
Average: 141.9588
Monoisotopic: 141.940784382
Chemical Formula
HNa2O4P
InChI Key
BNIILDVGGAEEIG-UHFFFAOYSA-L
InChI
InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2
IUPAC Name
disodium hydrogen phosphate
SMILES
[Na+].[Na+].OP([O-])([O-])=O

Pharmacology

Indication

Used to treat constipation or to clean the bowel before a colonoscopy Label.

Associated Therapies
Pharmacodynamics

Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.

Mechanism of action

Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineThe serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Sodium phosphate, dibasic.
2,5-Dimethoxy-4-ethylthioamphetamineThe serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Sodium phosphate, dibasic.
4-Bromo-2,5-dimethoxyamphetamineThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Sodium phosphate, dibasic.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium phosphate, dibasic.
AclidiniumThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aclidinium.
AgmatineThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Agmatine.
AlcuroniumThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alcuronium.
AlfentanilThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Alloin.
AlmasilateThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Almasilate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [PubMed:17652123]
  2. Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [PubMed:18645612]
  3. Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [PubMed:19298584]
  4. Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [PubMed:20958267]
  5. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
  6. FDA Guide: Sodium Phosphate Tablet [Link]
  7. ChemIDPlus: Sodium Phosphate [Link]
External Links
KEGG Compound
C13558
ChemSpider
22625
ChEBI
34683
ChEMBL
CHEMBL1060

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Not Yet RecruitingPreventionCataracts / Ocular inflammatory conditions1
3CompletedNot AvailableColonoscopy1
3CompletedTreatmentCataracts2
3RecruitingTreatmentBowel preparation therapy1
3Unknown StatusNot AvailableMalignant Neoplasm of Colon1
4Active Not RecruitingTreatmentCarpal Tunnel Syndrome (CTS)1
4CompletedTreatmentColon Cleansing1
4CompletedTreatmentOSAS (Obstructive Sleep Apneas Syndrome) / Psoriasis1
Not AvailableRecruitingTreatmentAngle-Closure Glaucoma / Glaucoma, Closed-Angle / Glaucoma, Narrow-Angle1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous
Powder, for solutionIntraocular
Kit; solutionIntraocular
LiquidOral
KitIntravenous
SolutionUnknown
Tablet, coatedOral
LiquidBuccal
SprayBuccal
Kit; solutionIntraocular; Irrigation
LiquidTopical
Tablet, effervescentOral
TabletOral
InjectionIntravenous
SolutionOral
EnemaRectal
SolutionIntravenous
SolutionRespiratory (inhalation)
PowderOral
IrrigantIrrigation
SolutionIrrigation
LiquidIrrigation
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7687075No2010-03-302028-06-22Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-1ChemAxon
pKa (Strongest Acidic)1.8ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area83.42 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity12.41 m3·mol-1ChemAxon
Polarizability5.24 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal oxoanionic compounds
Sub Class
Alkali metal phosphates
Direct Parent
Alkali metal phosphates
Alternative Parents
Inorganic sodium salts / Inorganic oxides
Substituents
Alkali metal phosphate / Inorganic sodium salt / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
sodium phosphate (CHEBI:34683)

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Not Available
Specific Function
Not Available
Gene Name
SLC20A1
Uniprot ID
Q8WUM9
Uniprot Name
Sodium-dependent phosphate transporter 1
Molecular Weight
73699.01 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Virus receptor activity
Specific Function
Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
Gene Name
SLC20A2
Uniprot ID
Q08357
Uniprot Name
Sodium-dependent phosphate transporter 2
Molecular Weight
70391.755 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
Gene Name
SLC34A1
Uniprot ID
Q06495
Uniprot Name
Sodium-dependent phosphate transport protein 2A
Molecular Weight
68936.53 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
Gene Name
SLC34A2
Uniprot ID
O95436
Uniprot Name
Sodium-dependent phosphate transport protein 2B
Molecular Weight
75758.535 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
Gene Name
SLC34A3
Uniprot ID
Q8N130
Uniprot Name
Sodium-dependent phosphate transport protein 2C
Molecular Weight
63548.94 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]

Drug created on July 11, 2018 11:31 / Updated on December 02, 2019 10:13